J. Safra Sarasin Holding AG Boosts Holdings in DexCom, Inc. $DXCM

J. Safra Sarasin Holding AG boosted its holdings in DexCom, Inc. (NASDAQ:DXCM) by 57.9% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 36,283 shares of the medical device company’s stock after purchasing an additional 13,299 shares during the quarter. J. Safra Sarasin Holding AG’s holdings in DexCom were worth $2,408,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of DXCM. CVA Family Office LLC lifted its holdings in shares of DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of DexCom by 2.5% during the third quarter. GAMMA Investing LLC now owns 7,043 shares of the medical device company’s stock worth $474,000 after acquiring an additional 169 shares during the last quarter. IFP Advisors Inc grew its stake in DexCom by 24.7% during the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock valued at $61,000 after acquiring an additional 178 shares in the last quarter. Inspire Investing LLC grew its stake in DexCom by 6.1% during the third quarter. Inspire Investing LLC now owns 3,139 shares of the medical device company’s stock valued at $211,000 after acquiring an additional 180 shares in the last quarter. Finally, Personal CFO Solutions LLC increased its holdings in DexCom by 5.0% in the 3rd quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock valued at $260,000 after acquiring an additional 185 shares during the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

NASDAQ:DXCM opened at $62.80 on Wednesday. The firm has a market capitalization of $24.17 billion, a PE ratio of 29.90, a PEG ratio of 1.21 and a beta of 1.48. The stock’s fifty day moving average is $69.75 and its 200 day moving average is $67.37. DexCom, Inc. has a fifty-two week low of $54.11 and a fifty-two week high of $89.98. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.59 and a current ratio of 1.88.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.03. DexCom had a net margin of 17.94% and a return on equity of 32.12%. The business had revenue of $1.26 billion for the quarter, compared to analysts’ expectations of $1.25 billion. During the same quarter in the previous year, the business posted $0.45 earnings per share. The business’s revenue was up 13.1% compared to the same quarter last year. On average, sell-side analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have commented on DXCM. Wells Fargo & Company decreased their price target on shares of DexCom from $93.00 to $85.00 and set an “overweight” rating on the stock in a research note on Friday, February 13th. Barclays reaffirmed an “underweight” rating and issued a $72.00 target price (up from $71.00) on shares of DexCom in a report on Friday, February 13th. Mizuho increased their price target on DexCom from $78.00 to $90.00 and gave the company an “outperform” rating in a research note on Friday, February 13th. BTIG Research reissued a “buy” rating and set a $85.00 price target on shares of DexCom in a research note on Monday, March 9th. Finally, Canaccord Genuity Group set a $95.00 price objective on DexCom and gave the stock a “buy” rating in a research note on Friday, February 13th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $86.50.

Insider Activity at DexCom

In related news, EVP Michael Jon Brown sold 1,700 shares of the company’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $64.85, for a total transaction of $110,245.00. Following the transaction, the executive vice president directly owned 112,904 shares in the company, valued at approximately $7,321,824.40. This represents a 1.48% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.